Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer Sells 12,000 Shares

Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer sold 12,000 shares of Paysign stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $2.85, for a total value of $34,200.00. Following the completion of the sale, the chief executive officer now owns 9,036,886 shares in the company, valued at approximately $25,755,125.10. The trade was a 0.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mark Newcomer also recently made the following trade(s):

• On Tuesday, January 21st, Mark Newcomer sold 61,000 shares of Paysign stock. The shares were sold at an average price of $2.89, for a total value of $176,290.00.
• On Monday, December 9th, Mark Newcomer sold 41,000 shares of Paysign stock. The stock was sold at an average price of $3.31, for a total value of $135,710.00.
• On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The shares were sold at an average price of $3.27, for a total value of $81,750.00.
• On Monday, November 18th, Mark Newcomer sold 40,000 shares of Paysign stock. The stock was sold at an average price of $3.24, for a total transaction of $129,600.00.

Paysign Trading Up 1.4 %

Shares of PAYS stock opened at $2.90 on Friday. Paysign, Inc. has a twelve month low of $2.70 and a twelve month high of $5.59. The company’s 50-day moving average price is $3.16 and its 200-day moving average price is $3.91. The stock has a market cap of $155.30 million, a price-to-earnings ratio of 19.33 and a beta of 0.95.

Paysign (NASDAQ:PAYS) last posted its earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.02. The company had revenue of $15.26 million for the quarter, compared to analyst estimates of $14.96 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. During the same period in the previous year, the business posted $0.02 EPS. As a group, equities research analysts predict that Paysign, Inc. will post 0.21 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on PAYS. Barrington Research restated an “outperform” rating and set a $7.00 price target on shares of Paysign in a research report on Monday, November 4th. Lake Street Capital assumed coverage on Paysign in a report on Friday, December 20th. They set a “buy” rating and a $6.00 target price on the stock.

Institutional Investors Weigh In On Paysign

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAYS. Renaissance Technologies LLC lifted its stake in shares of Paysign by 25.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock valued at $6,484,000 after purchasing an additional 301,000 shares during the last quarter. Royce & Associates LP acquired a new position in Paysign in the third quarter valued at about $814,000. Barclays PLC boosted its stake in Paysign by 327.4% during the third quarter. Barclays PLC now owns 47,090 shares of the company’s stock worth $173,000 after buying an additional 36,071 shares during the period. Rhumbline Advisers increased its position in shares of Paysign by 25.1% during the second quarter. Rhumbline Advisers now owns 35,835 shares of the company’s stock valued at $154,000 after acquiring an additional 7,190 shares during the last quarter. Finally, Joule Financial LLC purchased a new stake in shares of Paysign in the 3rd quarter valued at approximately $1,478,000. Institutional investors and hedge funds own 25.89% of the company’s stock.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.